Is It Too Late to Buy Moderna Stock?
Moderna's (NASDAQ: MRNA) upward share price momentum appears to be fading. In 2020, the biotech's stock skyrocketed by more than 430% due to investors' excitement over its COVID-19 vaccine, mRNA-1273. Moderna started off this year on a positive note as well, with the stock tacking on over 75% more by early February. Since then, though, it's been mainly downhill.
Some investors may be of the view that the last several weeks were merely a temporary pullback. Others could see Moderna as a once-hot biotech stock with an unjustifiably high valuation that's in the early innings of a sustained decline. If the latter take is right, the opportunity to make solid returns with Moderna has gone by the wayside. But is it really too late to buy Moderna stock?
Image source: Getty Images.
Source Fool.com
